Pre-complexing cytokine-activated cord-blood NK cells with the CD30xCD16A engager AFM13 yielded an overall response rate 92.9% with reassuring tolerability in CD30-positive lymphoma [34]. This evidence concerns the gene TNFRSF8 and lymphoma.